Date

Monday, 29 November 2010

Location

European Medicines Agency, Amsterdam, the Netherlands

The meeting is identifying priorities for and the optimal design of studies on drug development in paediatric heart failure (HF) for the purpose of the evaluation of paediatric investigation plans. The main topics include new drug classes in the pipeline and priority list for HF drugs in children, types of paediatric HF to be studied, trial design issues and the establishment of a paediatric cardiology network.

Documents

Share this page